ACCCBUZZ BLOG

While ADCs have emerged as a promising development for patients with NSCLC, they present unique challenges in clinical practice, such as optimal patient selection, treatment sequencing, and toxicity management. ADCs can also elicit significant adverse events, particularly when combined with immunotherapy, raising concerns about overlapping toxicities and the need for close monitoring for treatment-related complications.

ACCC is committed to helping cancer care team members, patients, and caregivers understand how bispecific antibody treatments fit within the cancer care continuum, how they differ from CAR T-cell therapy, and the education and resources available to patients and their families.

Explore the role of cardio-oncology in understanding and managing potential cardiovascular complications of immune checkpoint inhibitors.

ACCCBuzz recognizes June as Cancer Immunotherapy Month.

ACCC recently announced a collaboration with the Digital Medicine Society on a project to develop a risk prediction tool for cytokine release syndrome.

As immune checkpoint inhibitors have become the standard of care for eligible patients with NSCLC, frequent monitoring of irAEs as well as provider and patient education on the signs and symptoms of pneumonitis can ensure improved clinical outcomes for patients.

Managing immunotherapy related adverse events (irAEs) requires a team-based effort, with pharmacists playing an integral role in their identification and management within both outpatient and inpatient multidisciplinary teams.

June is Cancer Immunotherapy Month, and ACCC is highlighting the important work that it and its partners are doing to increase patient access to these novel therapies.

The first post in ACCC's Subspeciality Immuno-Oncology Insights series—the APP perspective and real-world strategies for tackling current challenges in the delivery of immunotherapies for cancer.

Learn how ACCC's bispecific antibody initiative “Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management”—developed in partnership with the Society for Immunotherapy of Cancer—will help expand the use of these novel therapies and optimize care for patients with cancer.

In recognizing Cancer Immunotherapy Month and National Cancer Survivors Day (June 5), ACCC is highlighting the resources it has created to assist the multidisciplinary team in creating and adapting survivorship care plans to meet these patients’ unique needs and support toxicity management for better outcomes.

While precision medicine in cancer care is becoming more widespread, its rapid evolution in oncology requires ongoing discussion. ACCC’s podcast, CANCER BUZZ, features lively expert discussions about emergent issues in cancer care. Here we highlight some of those podcasts.

In launching its new campaign, Transforming Complex To Clear, ACCC brought together expert panelists to discuss effective practices and offer tips to address current barriers to biomarker testing in the community setting.

Liquid biopsy, a genetic test that can eliminate some of the most serious potential drawbacks of traditional tissue biopsy, is gaining more traction in cancer care. But there remain significant barriers to its widespread use.

To help address the ongoing prevalence of colorectal cancer, ACCC is inviting its members to submit proposals for quality improvement initiatives in treating metastatic forms of this cancer.

Montana is one of the most rural states in the U.S., with nearly half of its population living in rural regions. Accordingly, accessing healthcare services can be difficult for Montana’s citizens, and gaining access to clinical trials is particularly challenging.

Recent advances in immuno-oncology (IO) therapies have led to rapid, effective treatments for subsets of patients with cancers that have proven resistant to conventional treatments.

Growing knowledge of NSCLC subtypes and molecular biomarkers for this disease has led to changes in how NSCLC is diagnosed and staged.

In recognition of Cancer Immunotherapy Month, ACCCBuzz talked to Sigrun Hallmeyer, MD, the chair of the ACCC Immuno-Oncology Institute’s Executive Committee.